Veracyte earnings release, May 5, 2026

Veracyte, Inc. (VCYT) · Form 8-K, Item 2.02 · Filed · SEC filing

Veracyte Announces First Quarter 2026 Financial Results

Grew total revenue to $139.1 million and testing revenue to $135.1 million, representing increases of 21% and 26% year-over-year, respectively

Conference call and webcast today at 4:30 p.m. ET

SOUTH SAN FRANCISCO, Calif., May 5, 2026 --- Veracyte, Inc. (Nasdaq: VCYT), a leading cancer diagnostics company, today announced financial results for the first quarter ended March 31, 2026.

“We had a strong start to the year, with Decipher and Afirma volume growth surpassing expectations and exceeding our profitability targets,” said Marc Stapley, Veracyte’s CEO. “Our growing clinical evidence continues to set us apart, and this quarter strengthened it even further. We believe we are approaching an inflection point with the upcoming launches of Prosigna LDT and TrueMRD, two of the most significant new products in our history, creating meaningful opportunities for market expansion in Breast, Bladder and other cancers, alongside continued growth in our Prostate and Thyroid businesses.”

Key Financial Highlights

For the three-month period ended March 31, 2026, as compared to the same period in 2025:

• Increased total revenue by 21% to $139.1 million and testing revenue by 26% to $135.1 million, driven by Decipher growth of 30% to $86.5 million and Afirma growth of 21% to $46.4 million.

• Increased total volume by 17% to 47,615 tests and testing volume by 19% to 45,248 tests, driven by Decipher growth of 24% to approximately 28,000 tests and Afirma growth of 12% to approximately 17,200 tests.

• Recorded GAAP net income of $28.7 million, or 20.6% of revenue, and delivered adjusted EBITDA of $42.8 million, or 30.8% of revenue.

• Generated $35.2 million of cash from operations to end the quarter with $439.1 million of cash, cash equivalents, and short-term investments as of March 31, 2026.

Key Business Highlights

• Advanced the evidence pipeline for Decipher with enrollment completed for GUIDANCE and G-MAJOR phase III trials.

• Announced data published in

European Urology Oncology showing Decipher’s ability to stratify risk among patients undergoing active surveillance.

• Announced more than 15 studies featuring Decipher Prostate and Decipher Bladder will be presented at the AUA Annual Meeting next week, including the expanding impact of Decipher Prostate in studies using real-world data.

• Strengthened the leadership team with the appointments of Kevin Haas as Chief Development and Technology Officer and Tracy Ward as Chief Human Resources Officer.

A reconciliation of GAAP to non-GAAP financial measures has been provided in the tables included in this press release. An explanation of these measures is also included below under the heading "Note Regarding Use of Non-GAAP Financial Measures."

First Quarter 2026 Financial Results

Total revenue for the first quarter of 2026 was $139.1 million, an increase of 21% compared to $114.5 million reported in the first quarter of 2025. Testing revenue was $135.1 million, an increase of 26% compared to $107.3 million in the first quarter of 2025, driven by growth in our Decipher Prostate and Afirma tests. Product revenue was $3.7 million, an increase of 3% compared to $3.6 million in the first quarter of 2025. Biopharmaceutical and other revenue was $0.3 million, an expected decrease compared to $3.6 million in the first quarter of 2025 given the restructuring and liquidation proceedings of Veracyte SAS.

Total gross margin for the first quarter of 2026 was 73%, compared to 69% in the first quarter of 2025. Non-GAAP gross margin was 76%, compared to 72% in the first quarter of 2025.

Operating expenses were $78.5 million for the first quarter of 2026 compared to $76.6 million in the first quarter of 2025. Non-GAAP operating expenses grew 7% to $64.6 million compared to $60.5 million in the first quarter of 2025.

Net income for the first quarter of 2026 was $28.7 million, an improvement of 307% compared to the first quarter of 2025. Diluted net earnings per common share was $0.35, an improvement of $0.26 compared to the first quarter of 2025. Non-GAAP diluted net earnings per common share was $0.52, an increase of $0.21 compared to the first quarter of 2025. Net cash provided by operating activities in the first three months of 2026 was $35.2 million, an improvement of $29.9 million compared to the same period in 2025.

Adjusted EBITDA for the first quarter of 2026 was $42.8 million, an improvement of 73% compared to the first quarter of 2025, representing 30.8% of revenue compared to 21.6% of revenue in the same period in 2025.

2026 Financial Outlook

The company is raising 2026 total revenue guidance to $582 million to $592 million, or 13% to 14% growth, from prior guidance of $570 to $582 million, or 10% to 13% growth. The company is also raising testing revenue guidance to $570 million to $580 million, or 16% to 18% growth, excluding the contribution from new tests.

Additionally, the company is raising guidance for adjusted EBITDA margin to greater than 26%, from approximately 25% prior.

The company is unable to provide a quantitative reconciliation of expected adjusted EBITDA margin to the most directly comparable forward-looking GAAP measure without unreasonable effort, because of the inherent difficulty in accurately forecasting the occurrence and financial impact of the various adjusting items necessary for such reconciliations that have not yet occurred, that are dependent on various factors, are out of the company’s control, or that cannot be reasonably predicted. Such adjustments include, but are not limited to, acquisition-related expenses, and other adjustments. Any associated estimate of these items and their impact on GAAP performance for the guidance period could vary materially. For more information on the non-GAAP financial measures, please refer to the section titled “Note Regarding Use of Non-GAAP Financial Measures” at the end of this press release.... (truncated)cast Details

Veracyte will host a conference call and webcast today at 4:30 p.m. Eastern Time to discuss the company's financial results and provide a general business update. The conference call will be webcast live from the company’s website and will be available via the following link: https://edge.media-server.com/mmc/p/293q6w6a. The webcast should be accessed 10 minutes prior to the conference call start time. A replay of the webcast will be available for one year following the conclusion of the live broadcast and will be accessible on the company’s website at https://investor.veracyte.com/events-presentations.

The conference call dial-in can be accessed by registering via the following link: https://register-conf.media-server.com/register/BIe7dfa54183624bef85d5dea0e7c81024.

About Veracyte

Veracyte (Nasdaq: VCYT) is a global diagnostics company whose vision is to transform cancer care for patients all over the world. We empower clinicians with the high-value insights they need to guide and assure patients at pivotal moments in the race to diagnose and treat cancer. Our Veracyte Diagnostics Platform delivers high-performing cancer tests that are fueled by broad genomic and clinical data, deep bioinformatic and AI capabilities, and a powerful evidence-generation engine, which ultimately drives durable reimbursement and guideline inclusion for our tests, along with new insights to support continued innovation and pipeline development.

For more information, please visit www.veracyte.com or follow us on

LinkedIn or

X (Twitter).

Financial statements

Income Statement

Three Months Ended March 31, – 20262025
Revenue:Testing revenue135,091107,309
Revenue:Product revenue3,6793,580
Revenue:Biopharmaceutical and other revenue3013,584
Revenue:Total revenue139,071114,473
Cost of revenue: (1)Cost of testing revenue33,30628,260
Cost of revenue: (1)Cost of product revenue1,8911,422
Cost of revenue: (1)Cost of biopharmaceutical and other revenue82,698
Cost of revenue: (1)Intangible asset amortization - cost of revenue2,7072,585
Cost of revenue: (1)Total cost of revenue37,91234,965
Cost of revenue: (1)Gross profit101,15979,508
Operating expenses: (1)Research and development27,09817,720
Operating expenses: (1)Selling and marketing27,15624,454
Operating expenses: (1)General and administrative23,68033,808
Operating expenses: (1)Intangible asset amortization - operating expenses579622
Operating expenses: (1)Total operating expenses78,51376,604
Operating expenses: (1)Income from operations22,6462,904
Operating expenses: (1)Other income, net7,3284,524
Operating expenses: (1)Income before income taxes29,9747,428
Operating expenses: (1)Income tax provision1,267381
Operating expenses: (1)Net income28,7077,047
Earnings per share:Basic0.360.09
Earnings per share:Diluted0.350.09
Shares used to compute earnings per common share:Basic79,536,60178,028,254
Shares used to compute earnings per common share:Diluted81,313,58880,056,024

Income Statement

Three Months Ended March 31,

Three Months Ended March 31, – 20262025
Cost of revenue1,099520
Research and development2,6802,066
Selling and marketing2,3991,958
General and administrative6,5836,414
Total stock-based compensation expense12,76110,958

Income Statement

VERACYTE, INC. – RECONCILIATION OF U.S. GAAP to NON-GAAP FINANCIAL MEASURES – (Unaudited) – Three Months Ended March 31, – 2026VERACYTE, INC. – RECONCILIATION OF U.S. GAAP to NON-GAAP FINANCIAL MEASURES – (Unaudited) – Three Months Ended March 31, – 2025
Reconciliation of Non-GAAP Cost of Revenue:GAAP cost of testing revenue33,30628,260
Reconciliation of Non-GAAP Cost of Revenue:Stock-based compensation expense-1,099-446
Reconciliation of Non-GAAP Cost of Revenue:Other adjustments (1)-300
Reconciliation of Non-GAAP Cost of Revenue:Non-GAAP cost of testing revenue31,90727,814
Reconciliation of Non-GAAP Cost of Revenue:GAAP cost of product revenue1,8911,422
Reconciliation of Non-GAAP Cost of Revenue:Stock-based compensation expense-1
Reconciliation of Non-GAAP Cost of Revenue:Other adjustments (1)11
Reconciliation of Non-GAAP Cost of Revenue:Non-GAAP cost of product revenue1,9021,421
Reconciliation of Non-GAAP Cost of Revenue:GAAP cost of biopharmaceutical and other revenue82,698
Reconciliation of Non-GAAP Cost of Revenue:Stock-based compensation expense-73
Reconciliation of Non-GAAP Cost of Revenue:Non-GAAP cost of biopharmaceutical and other revenue82,625
Reconciliation of Non-GAAP Gross Margin:GAAP Gross Profit101,15979,508
Reconciliation of Non-GAAP Gross Margin:GAAP Gross Margin72.769.5
Reconciliation of Non-GAAP Gross Margin:Amortization of intangible assets2,7072,585
Reconciliation of Non-GAAP Gross Margin:Stock-based compensation expense1,099520
Reconciliation of Non-GAAP Gross Margin:Other adjustments (1)289
Reconciliation of Non-GAAP Gross Margin:Non-GAAP Gross Profit105,25482,613
Reconciliation of Non-GAAP Gross Margin:Non-GAAP Gross Margin75.772.2

Income Statement

VERACYTE, INC. – RECONCILIATION OF U.S. GAAP to NON-GAAP FINANCIAL MEASURES – (Unaudited) – Three Months Ended March 31, – 2026VERACYTE, INC. – RECONCILIATION OF U.S. GAAP to NON-GAAP FINANCIAL MEASURES – (Unaudited) – Three Months Ended March 31, – 2025
Reconciliation of Adjusted EBITDA:GAAP Net Income (Loss)28,7077,047
Reconciliation of Adjusted EBITDA:GAAP Net Income (Loss) as a % of Revenue20.66.2
Reconciliation of Adjusted EBITDA:Amortization of intangible assets3,2863,207
Reconciliation of Adjusted EBITDA:Depreciation expense2,1442,155
Reconciliation of Adjusted EBITDA:Stock-based compensation expense12,76110,958
Reconciliation of Adjusted EBITDA:Acquisition related expenses (1)-3671,352
Reconciliation of Adjusted EBITDA:Other expense (income), net (2)-3,478-2,976
Reconciliation of Adjusted EBITDA:Other adjustments (3)-1,5202,591
Reconciliation of Adjusted EBITDA:Income tax expense (benefit)1,267381
Reconciliation of Adjusted EBITDA:Adjusted EBITDA42,80024,715
Reconciliation of Adjusted EBITDA:Adjusted EBITDA as a % of Revenue30.821.6
Reconciliation of Non-GAAP Net Income (Loss)GAAP Net Income (Loss)28,7077,047
Reconciliation of Non-GAAP Net Income (Loss)Amortization of intangible assets3,2863,207
Reconciliation of Non-GAAP Net Income (Loss)Stock-based compensation expense12,76110,958
Reconciliation of Non-GAAP Net Income (Loss)Acquisition related expenses (1)-3671,352
Reconciliation of Non-GAAP Net Income (Loss)Other adjustments (3)-1,5202,591
Reconciliation of Non-GAAP Net Income (Loss)Tax adjustments (4)-753-679
Reconciliation of Non-GAAP Net Income (Loss)Non-GAAP Net Income42,11424,476
Reconciliation of Non-GAAP Earnings per ShareDiluted earnings per share, GAAP0.350.09
Reconciliation of Non-GAAP Earnings per ShareAmortization of intangible assets0.040.04
Reconciliation of Non-GAAP Earnings per ShareStock-based compensation expense0.160.14
Reconciliation of Non-GAAP Earnings per ShareAcquisition related expenses (1)0.02

Balance Sheet (in thousands)

VERACYTE, INC. – CONDENSED CONSOLIDATED BALANCE SHEETS – March 31, – 2026 – (Unaudited)VERACYTE, INC. – CONDENSED CONSOLIDATED BALANCE SHEETS – December 31, – 2025 – (See Note 1)
Current assets:Cash and cash equivalents263,136362,578
Current assets:Short-term investments175,92450,311
Current assets:Accounts receivable50,11244,660
Current assets:Supplies21,41620,546
Current assets:Prepaid expenses and other current assets11,58710,281
Current assets:Total current assets522,175488,376
Current assets:Property, plant and equipment, net22,65222,192
Current assets:Right-of-use assets, operating leases35,86536,599
Current assets:Intangible assets, net85,86389,148
Current assets:Goodwill767,154767,154
Current assets:Restricted cash1,6571,648
Current assets:Other assets1,034902
Current assets:Total assets1,436,4001,406,019
Current liabilities:Accounts payable6,9084,593
Current liabilities:Accrued liabilities43,12948,801
Current liabilities:Current portion of deferred revenue7491,160
Current liabilities:Current portion of acquisition-related contingent consideration9821,332
Current liabilities:Current portion of operating lease liabilities4,3474,051
Current liabilities:Total current liabilities56,11559,937
Current liabilities:Deferred tax liabilities636646
Current liabilities:Acquisition-related contingent consideration, net of current portion257257
Current liabilities:Operating lease liabilities, net of current portion34,98635,603
Current liabilities:Total liabilities91,99496,443
Current liabilities:Total stockholders’ equity1,344,4061,309,576
Current liabilities:Total liabilities and stockholders’ equity1,436,4001,406,019

Cash Flow

VERACYTE, INC. – CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS – (Unaudited) – Three Months Ended March 31, – 2026VERACYTE, INC. – CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS – (Unaudited) – Three Months Ended March 31, – 2025
Operating activitiesNet income28,7077,047
Adjustments to reconcile net income to net cash provided by operating activities:Depreciation and amortization5,4305,362
Adjustments to reconcile net income to net cash provided by operating activities:Loss on disposal of property, plant and equipment366
Adjustments to reconcile net income to net cash provided by operating activities:Stock-based compensation12,76110,958
Adjustments to reconcile net income to net cash provided by operating activities:Deferred income taxes-1015
Adjustments to reconcile net income to net cash provided by operating activities:Noncash lease expense732904
Adjustments to reconcile net income to net cash provided by operating activities:Revaluation of acquisition-related contingent consideration-350-1,954
Adjustments to reconcile net income to net cash provided by operating activities:Effect of foreign currency on operations-80-1,585
Adjustments to reconcile net income to net cash provided by operating activities:Amortization of discount on short-term investments-614-882
Changes in operating assets and liabilities:Accounts receivable-5,567-7,053
Changes in operating assets and liabilities:Supplies-870-2,298
Changes in operating assets and liabilities:Prepaid expenses and other current assets-1,306-2,928
Changes in operating assets and liabilities:Other assets-132122
Changes in operating assets and liabilities:Operating lease liabilities-319-577
Changes in operating assets and liabilities:Accounts payable2,5877,120
Changes in operating assets and liabilities:Accrued liabilities and deferred revenue-6,120-8,889
Changes in operating assets and liabilities:Net cash provided by operating activities35,2155,362
Investing activitiesPurchase of short-term investments-124,999-49,999
Investing activitiesPurchases of property, plant and equipment-2,962-1,819
Investing activitiesNet cash used in investing activities-127,961-51,818
Financing activitiesPayment of taxes on vested restricted stock units-9,364-9,451
Financing activitiesProceeds from the exercise of common stock options and employee stock purchases2,7352,967
Financing activitiesNet cash used in financing activities-6,629-6,484
Financing activitiesDecrease in cash, cash equivalents and restricted cash-99,375-52,940
Financing activitiesEffect of foreign currency on cash, cash equivalents and restricted cash-5874
Financing activitiesNet decrease in cash, cash equivalents and restricted cash-99,433-52,866
Financing activitiesCash, cash equivalents and restricted cash at beginning of period364,226240,631
Financing activitiesCash, cash equivalents and restricted cash at end of period264,793187,765
Full release

Cautionary Note Regarding Forward-Looking Statements

This press release contains forward-looking statements, including, but not limited to our statements related to our plans, objectives, and expectations (financial and otherwise), including with respect to our 2026 financial and operating results; and our intentions with respect to our tests and products, including upcoming product launches. Forward-looking statements can be identified by words such as: “appears,” “anticipate,” “intend,” “plan,” “expect,” “believe,” “should,” “may,” “could,” “would,” “will,” “enable,” “positioned,” “offers,” “designed,” “ultimately,” “strategic,” “outlook,” “guidance,” and similar references to future periods. Actual results may differ materially from those projected or suggested in any forward-looking statements. These statements involve risks and uncertainties, which could cause actual results to differ materially from our predictions, and include, but are not limited to: our ability to launch, commercialize and receive reimbursement for our products; our ability to execute on our business strategies relating to the C2i Genomics acquisition, integration of the business and the realization of expected benefits and synergies; our ability to demonstrate the validity and utility of our genomic tests and biopharma and other offerings; our ability to continue executing on our business plan; our ability to continue to scale our global operations and enhance our internal control environment; the impact of the war in Ukraine and other regional conflicts on European economies; the impact of foreign currency fluctuations, volatile interest rates, inflation, the impact of legislation and policies enacted by the current U.S. administration; turmoil in the global banking and finance system; the ongoing conflict in the Middle East; and the performance and utility of our tests in the clinical environment. Additional factors that may impact these forward-looking statements can be found under the caption “Risk Factors” in our Annual Report on Form 10-K filed on February 26, 2026, as well as in other documents that we may file from time to time with the Securities and Exchange Commission. Copies of these documents, when available, may be found in the Investors section of our website at investor.veracyte.com. These forward-looking statements speak only as of the date hereof and, except as required by law, we specifically disclaim any obligation to update these forward-looking statements or reasons why actual results might differ, whether as a result of new information, future events or otherwise.

Note Regarding Use of Non-GAAP Financial Measures

In addition to the financial measures prepared in accordance with generally accepted accounting principles (GAAP), this press release and the accompanying tables contain, and reference certain non‐GAAP results including non-GAAP gross margin, non-GAAP operating expenses, adjusted EBITDA, adjusted EBITDA as a percentage of revenue (also referred to as adjusted EBITDA margin), non-GAAP net income, and non-GAAP earnings per share (EPS) and non-GAAP weighted average shares outstanding. These non-GAAP financial measures are not meant to be considered superior to or a substitute for financial measures calculated in accordance with GAAP, and investors are cautioned that there are material limitations associated with the use of non-GAAP financial measures as an analytical tool.

We use non-GAAP financial measures to internally evaluate and analyze financial results. We believe these non-GAAP financial measures provide investors with useful supplemental information about the financial performance of our business, enable comparison of financial results between periods where certain items may vary independent of business performance, and enable comparison of our financial results with other public companies, many of which present similar non-GAAP financial measures. However, the non-GAAP financial measures we present may be different from those used by other companies, including similarly titled measures.... (truncated)nses relating to our acquisitions of Decipher Biosciences, HalioDx and C2i Genomics, impairment charges associated with the nCounter license and other biopharmaceutical services related to HalioDx intangible assets, all stock-based compensation and certain costs related to restructuring from all of our non-GAAP financial measures as well as depreciation and income tax items from our adjusted EBITDA and adjusted EBITDA as a percentage of revenue. Beginning in the second quarter of 2024, we changed our non-GAAP policy to exclude all stock-based compensation to align with our peers and we have also excluded all stock-based compensation from our prior period non-GAAP financial measures. Management has excluded the effects of these items in non-GAAP financial measures to help investors gain a better understanding of the core operating results and future prospects of the company, consistent with how management measures and forecasts the company's performance, especially when comparing such results to previous periods or forecasts. The company encourages investors to carefully consider its results under GAAP, together with its supplemental non‐GAAP information and the reconciliation between these presentations. See “Reconciliation of U.S. GAAP to Non-GAAP Financial Measures” for a reconciliation of each non-GAAP measure presented to the comparable GAAP financial measure.

1. Cost of revenue, research and development, sales and marketing and general and administrative expenses include the following stock-based compensation related expenses:

# # #

Investors:

Kelly Gura investors@veracyte.com

619-393-1545

Media:

Molly Cornbleet media@veracyte.com

From SEC EDGAR. Analysis by Pear Digitals from the filing alone. Not investment advice. · Veracyte earnings · Latest earnings · Markdown

Screener

Plans

Premium and Pro coming soon.

Log in

New here?

Join the waitlist

Pear FMV opens to everyone soon. We'll email you when it does.